Head and Neck Oncology
Nanobiotix focuses on locally advanced head and neck squamous cell carcinoma, with clinical interest centered on patients who are not eligible for platinum-based chemotherapy and require treatment options aligned with radiotherapy-based care.
- Locally advanced head and neck squamous cell carcinoma
- Platinum-ineligible patients
- Elderly oncology populations
The sponsor’s activity in this area reflects a therapeutic emphasis on difficult-to-treat disease within head and neck cancer practice.
Radiation-Based Cancer Therapy
Its research portfolio includes the use of radiotherapy as a central treatment backbone, including settings where radiation is used alone or alongside cetuximab in head and neck squamous cell carcinoma.
- Radiotherapy
- Cetuximab
- Radiation-responsive solid tumours
This places the sponsor within the field of oncologic radiation treatment, with attention to local disease control and survival outcomes.
Intratumoral Cancer Treatment
Nanobiotix is active in intratumoral therapy, supporting research around direct tumour administration in solid tumour oncology and treatment activation within the tumour environment.
- Intratumoral injection
- Tumour-localised treatment
- Solid tumour targeting
The therapeutic interest here is centred on localised intervention for tumours that are managed through site-specific treatment approaches.
Combination Oncology Care
The sponsor’s trial activity includes combination cancer therapy, particularly the pairing of radiotherapy with cetuximab in locally advanced cancer.
- Combination treatment strategies
- Targeted therapy with radiotherapy
- Locoregional cancer management
This area reflects interest in therapeutic regimens for advanced head and neck malignancies requiring integrated oncology care.
